Full Text Available
Access Full Text at Repository
Search Results
-
Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development
Published in Biologics: Targets & Therapy (2026)Get full text
Online Article RSS Article